Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache

Last updated: February 4, 2023
Sponsor: Danish Headache Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pain (Pediatric)

Allergies & Asthma

Allergy (Pediatric)

Treatment

N/A

Clinical Study ID

NCT05669885
H-21067665
  • Ages 18-65
  • All Genders

Study Summary

To investigate whether sildenafil (phosphodiesterase 5 inhibitor) induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 to 65 years of age upon entry into screening
  • History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of HeadacheDisorders, 3rd Edition (ICHD-3)
  • ≥ 4 monthly headache days on average across the 3 months prior to screening
  • Provision of informed consent prior to initiation of any study-specificactivities/procedures

Exclusion

Exclusion Criteria:

  • > 1 mild traumatic injury to the head
  • History of any primary or secondary headache disorder prior to mild traumatic injuryto the head (except for infrequent episodic tension-type headache)
  • History of moderate or severe injury to the head
  • History of whiplash injury
  • History of craniotomy
  • History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, wouldpose a risk to subject safety or interfere with study evaluation, procedures orcompletion
  • The subject is at risk of self-harm or harm to others as evidenced by past suicidalbehavior
  • Female subjects of childbearing potential with a positive pregnancy test during anystudy visit
  • Cardiovascular disease of any kind, including cerebrovascular diseases
  • Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
  • Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
  • Initiation, discontinuation, or change of dosing of prophylactic medications within 2months prior to study inclusion
  • Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusionstart
  • Baseline headache intensity of >3 on an 11-point numeric rating scale (0 being noheadache, 10 being the worst imaginable headache)
  • Baseline headache with migraine-like features or self-reported baseline headache thatmimics the subjects' usual headache with migraine-like features

Study Design

Total Participants: 21
Study Start date:
January 02, 2023
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Danish Headache Center

    Copenhagen,
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.